iifl-logo

Syngene International Ltd Share Price

630.1
(-3.57%)
Apr 25, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open655
  • Day's High657
  • 52 Wk High960.6
  • Prev. Close653.4
  • Day's Low628
  • 52 Wk Low 607.65
  • Turnover (lac)27,823.55
  • P/E59.28
  • Face Value10
  • Book Value115.77
  • EPS11.03
  • Mkt. Cap (Cr.)25,363.86
  • Div. Yield0.19
View All Historical Data
Loading...
  • Open740
  • Day's High800.9
  • Spot794
  • Prev. Close744.45
  • Day's Low740
  • ViewShort Covering
  • Market Lot1,000
  • OI(Chg %)-8,03,000 (-32.25%)
  • Roll Over%10.69
  • Roll Cost-4.84
  • Traded Vol.54,28,000 (-24.14%)
View More Futures

Syngene International Ltd KEY RATIOS

Sector

Healthcare

Open

655

Prev. Close

653.4

Turnover(Lac.)

27,823.55

Day's High

657

Day's Low

628

52 Week's High

960.6

52 Week's Low

607.65

Book Value

115.77

Face Value

10

Mkt Cap (₹ Cr.)

25,363.86

P/E

59.28

EPS

11.03

Divi. Yield

0.19

Syngene International Ltd Corporate Action

24 Apr 2024

12:00 AM

Dividend

Dividend Amount: 1.25

Record Date: 28 Jun, 2024

arrow

8 Apr 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

24 Apr 2024

12:00 AM

AGM

Announcement Date: 24 Apr, 2024

arrow

Syngene International Ltd NEWS AND UPDATE

Syngene Reports ₹1,018 Crore Revenue in Q4 FY25
24 Apr 2025|01:21 PM

The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.

Read More
Syngene International reports better than expected Q4 results
24 Apr 2025|11:36 AM

The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.

Read More
Syngene Boosts Biologics Capacity with US Facility Acquisition
13 Mar 2025|01:40 PM

This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.

Read More
Syngene Reports 18% Profit Surge in Q3, Revenue Up 10.6%
24 Jan 2025|12:45 PM

The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Syngene International Ltd SHAREHOLDING SNAPSHOT

26 Apr, 2025|11:34 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.01%

Foreign: 0.00%

Indian: 52.73%

Non-Promoter- 40.98%

Institutions: 40.97%

Non-Institutions: 6.00%

Custodian: 0.29%

Share Price

Syngene International Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

402

401.4

400.8

400

Preference Capital

0

0

0

0

Reserves

3,789.5

3,217.5

2,891.2

2,418.3

Net Worth

4,191.5

3,618.9

3,292

2,818.3

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

2,601.4

2,179.4

2,011.9

1,423.1

yoy growth (%)

19.36

8.32

41.37

18.5

Raw materials

-749

-526.5

-519.4

-381.7

As % of sales

28.79

24.15

25.81

26.82

Employee costs

-697.8

-641.5

-572.2

-376.9

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

512.4

432.4

444.4

372.1

Depreciation

-309.7

-274.5

-219.3

-131.4

Tax paid

-87.9

-63.7

-104.2

-67

Working capital

-34.39

497.9

-955.5

480.2

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

19.36

8.32

41.37

18.5

Op profit growth

18.41

8.64

57.92

1.5

EBIT growth

16.6

-3.94

21.32

8.46

Net profit growth

-2.45

-1.89

34.87

6.19

View Ratios
Particulars (Rupees in Crores.)Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021

Gross Sales

3,642.4

3,488.6

3,192.9

2,604.2

2,184.3

Excise Duty

0

0

0

0

0

Net Sales

3,642.4

3,488.6

3,192.9

2,604.2

2,184.3

Other Operating Income

0

0

0

0

0

Other Income

103.8

90.6

70.9

52.8

99.6

Syngene International Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Max Healthcare Institute Ltd

MAXHEALTH

1,067.4

131.861,07,674.45138.240.14697.481.72

Apollo Hospitals Enterprise Ltd

APOLLOHOSP

6,953

85.681,02,964.19341.60.222,054.8569.62

Fortis Healthcare Ltd

FORTIS

654.65

250.350,453.8539.560.15366.87120.23

Narayana Hrudayalaya Ltd

NH

1,788

85.5636,720.5779.220.22865.0495.32

Global Health Ltd

MEDANTA

1,215.1

85.0433,370.6499.310624.4113.49

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Syngene International Ltd

Management

Register Office

Registrar Office

Chairperson

Kiran Mazumdar Shaw

Non Executive Director

Catherine Patricia Rosenberg

Independent Director

Paul Frederick Blackburn

Independent Director

Vijay Kuchroo

Managing Director & CEO

Jonathan Hunt

Lead Independent Director

Vinita Bali

Company Sec. & Compli. Officer

Priyadarshnini Mahapatra

Independent Director

Sharmila Karve

Independent Director

Kush Parmar

Executive Director & CFO

SIBAJI BISWAS

Independent Director

Nilanjan Roy

Independent Director

Manja Boerman

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Headquartered in India, the operations are driven by its highly qualified teams comprising ~6000 scientists and its state-of-the-art facilities, spread over 2.2 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore. The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers.Syngene International Limited was incorporated at Bangalore in 1993. The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited. The Companys health-related services extend across all major therapeutic areas and modalities. It provides end-to-end services within the Contract Research Organization (CRO) and a growing range of services within the Contract Development and Manufacturing Organization (CDMO). The primary target market for these services is the pharmaceutical and biotechnology (biotech) sectors. The same scientific capabilities that serve human health also serve nutrition, animal health, consumer goods, agri-chemicals, and specialty chemical sectors.During the year 1994-1995, the company pioneered in CRO services for both Chemistry and Biology. During the year 2001-2002, the company acquired a new facility inclusive of a cGMP
Read More

Company FAQs

What is the Syngene International Ltd share price today?

The Syngene International Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹630.1 today.

What is the Market Cap of Syngene International Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Syngene International Ltd is ₹25363.86 Cr. as of 25 Apr ‘25

What is the PE and PB ratio of Syngene International Ltd?

The PE and PB ratios of Syngene International Ltd is 59.28 and 5.67 as of 25 Apr ‘25

What is the 52 Week High and Low of Syngene International Ltd?

The 52-week high/low is the highest and lowest price at which a Syngene International Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Syngene International Ltd is ₹607.65 and ₹960.6 as of 25 Apr ‘25

What is the CAGR of Syngene International Ltd?

Syngene International Ltd's CAGR for 5 Years at 16.34%, 3 Years at 1.04%, 1 Year at -5.85%, 6 Month at -25.73%, 3 Month at -17.92% and 1 Month at -9.26%.

What is the shareholding pattern of Syngene International Ltd?

The shareholding pattern of Syngene International Ltd is as follows:
Promoters - 52.74 %
Institutions - 40.97 %
Public - 6.00 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.